Results 181 to 190 of about 3,663 (299)
Abstract Standardized trauma assessment frameworks often fail to account for the unique experiences and symptom presentations of minoritized populations, including Black, Indigenous, and people of color (BIPOC) and sexual and gender minority (SGM) individuals, leading to methodological inequity.
Krithika Prakash +4 more
wiley +1 more source
Physiological changes during pregnancy can trigger or worsen dermatological conditions, yet evidence‐based guidance for safe management remains limited. In a cross‐sectional survey of 273 pregnant women, 33.7% reported having a skin disease, and 56% experienced worsening of symptoms.
Frederikke Seeberg +4 more
wiley +1 more source
Risk factors for uterine dehiscence and rupture in case of vaginal birth after cesarean section. [PDF]
Hakim H +7 more
europepmc +1 more source
Laryngeal Dysfunction Following COVID‐19: A TriNetX Retrospective Cohort Study
COVID‐19 is associated with an increased incidence of new‐onset laryngeal dysfunction, including chronic cough, dysphagia, voice disorders, vocal fold paralysis, and laryngeal spasm, compared with uninfected controls. Risk peaks one to two years after infection for most outcomes and is influenced by factors such as hospitalization, mechanical ...
Cali Loblundo +4 more
wiley +1 more source
[Why is skin-to-skin contact still largely unknown in our maternity wards?] [PDF]
Rania S +4 more
europepmc +1 more source
[Prognostic factors for neonatal mortality at the Souro Sanou University Hospital in Bobo-Dioulasso, Burkina Faso: a cross-sectional study]. [PDF]
Ouattara CA +7 more
europepmc +1 more source
The study highlights the rising cervical cancer burden in Africa, where rates have increased since 1990. Key challenges include structural health inequalities, low HPV vaccination coverage, and limited screening. Projections suggest a continued increase in incidence, deaths, and DALYs by 2038, diverging further from global trends.
Yedong Huang +18 more
wiley +1 more source
ABSTRACT Introduction/Aims Tofersen is a gene‐targeted therapy for individuals with superoxide dismutase 1 (SOD1) (+) amyotrophic lateral sclerosis (ALS). Prior to U.S. Food and Drug Administration (FDA) approval, tofersen was made available through expanded access protocol.
Alison Wheeler +30 more
wiley +1 more source
[Placenta accreta: a retrospective descriptive study of 46 patients treated in the Obstetrics and Gynaecology Department of the Farhat Hached University Hospital in Sousse, Tunisia]. [PDF]
Bannour B +4 more
europepmc +1 more source
ABSTRACT Aims Neurogenic lower urinary tract dysfunction (NLUTD) describes a wide range of symptoms depending on neurologic diagnosis and the resulting bladder and sphincter dysfunction. This narrative review is designed to address the question regarding which NLUTD population benefits most from pelvic floor therapy and behavioral interventions, and ...
Sara M. Lenherr
wiley +1 more source

